MD Becker Partners is a boutique management and strategy consulting firm focusing on both public and private companies in the life science industry. We also work with venture capitalists, institutional investors, and others that provide capital to these companies.

As a strategic advisor and partner, we provide a full range of services to help our clients increase visibility, unlock stakeholder value and access resources to grow their business. To accomplish this, we integrate relations, strategy, and operational capabilities and apply them to carefully conceived and expertly enacted tactics.

Relations

MD Becker Partners - Relations
  • Financial, Media and Public Relations
  • Communications and Copywriting Services
  • Crisis and Issues Management
  • Disclosure Procedures and Compliance
  • New, Digital and Social Media

Strategy

MD Becker Partners - Strategy
  • Corporate Strategy and Brand Positioning
  • Business Development
  • Outsourced Due Diligence
  • Corporate Funding
  • Market Research

Operations

MD Becker Partners - Operations
  • Workout and Corporate Reorganization
  • Interim and Acting Management Solutions
  • Turnaround and Targeted Improvement
  • Project Management
  • Clinical and Regulatory Strategy & Filings

Quoted in the News

MD Becker Partners - Quoted in the news

6/27/2012 – “High Points and Hurdles: Immunotherapy Moves Forward” by Anita T. Shaffer of OncLive

5/7/2012 – “Insight: Training immune system to fight cancer comes of age” by Bill Berkrot of Reuters

3/2/2012 – “Biotech Stock Mailbag: Cyclacel Fallout, the Skinny on Vivus, Celldex’s Crash” by Adam Feuerstein of TheStreet.com

2/27/2012 – “Dendreon Shares Drop on Slowing Sales of Cancer Vaccine Provenge” by Brett Chase of Minyanville

1/26/2012 – “Amgen, Celgene, Roche Deals Signal M&A Frenzy for Drug Companies” by Brett Chase of Minyanville

1/5/2012 – “Dendreon reports spike in Provenge sales; shares soar” by Bill Berkrot of Reuters

10/11/2011 – “Nobel prize-winning science should incubate deals” by David Holley of The Deal

10/7/2011 – “Zytiga creeps up on Provenge prostate-cancer drug” by Ransdell Pierson of Reuters

8/23/2011 – “What’s a Cancer Drug Worth?” by Brett Chase of Minyanville

 

Press Releases and Events

MD Becker Partners - Press releases & events

October 4, 2012 – MD Becker Partners hosted its 3rd annual “Cancer Immunotherapy: A Long Awaited Reality” conference event in New York.  For more information, please Click Here for the Event Website.

September 24, 2012 – “Experts Discuss Challenges and Opportunities in the Development and Manufacturing of Medical Countermeasures; Alliance for Biosecurity and MD Becker Partners Jointly Publish New Industry Roundtable Report” press release

April 12, 2012 – “MD Becker Partners Releases White Paper: 2012 – A Pivotal Year for Alzheimer’s Disease Drug Development” press release

March 11-14, 2012 – MD Becker Partners sponsored ROTH Capital Partners’ 24th Annual Growth Stock Conference in Dana Point, California.  Michael Becker also moderated a fireside chat with industry experts titled “Identifying Strategic Value: M&A and Public Market Trends.”

November 10, 2011 – “MD Becker Partners Celebrates Third Successful Year in Business” press release

Select Client News

MD Becker Partners - Client news

10/1/2012 – “Bavarian Nordic Reports Preliminary Data from Phase 2 Trial of CV-301 in Metastatic Breast Cancer” press release

9/13/2012 – “Cyclacel Regains Compliance With NASDAQ Minimum Bid Price Listing Requirement” press release

8/8/2012 – “Agenus Announces Publication of Key Data Showing Antitumor Activity of Prophage Vaccine (HSPPC-96) in Clinical Cancer Research” press release

6/21/2012 – “Idera Pharmaceuticals Reports Preclinical Mechanism of Action Data on IMO-8400, a Novel TLR Inhibitor for Autoimmune Diseases” press release

4/17/2012 – “New Phase 2 Data From Brain Cancer Study With Agenus’ Prophage Vaccine (HSPPC-96) Presented at Plenary Session of AANS” press release

4/16/2012 – “Bavarian Nordic A/S – Report on the Results of the Annual General Meeting, held 16 April 2012″ press release

3/5/2012 – “Agenus Expands QS-21 License and Grants Right of First Negotiation to GlaxoSmithKline” press release